Articles published by Denali Therapeutics Inc.

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces $500 million Private Placement Equity Financing
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers BIIB DNLI
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Denali Therapeutics Announces Proposed Offering of Common Stock
From Denali Therapeutics Inc.
Via GlobeNewswire
Tickers DNLI
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.